Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 19/20 | 0.66 |
| ▸ | HTR1B | P28222 | 19/20 | 0.66 |
| ▸ | HTR1A | P08908 | 17/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5210961 | 0.91 | HTR1D (0.65) | HTR1DHTR1BHTR1A | |
| SCHEMBL5207125 | 0.91 | HTR1D (0.65) | HTR1DHTR1BHTR1A | |
| SCHEMBL5206892 | 0.86 | HTR1D (0.69) | HTR1DHTR1BHTR1A | |
| SCHEMBL5206900 | 0.86 | HTR1D (0.69) | HTR1DHTR1BHTR1A | |
| SCHEMBL6648620 | 0.86 | HTR1D (0.57) | HTR1DHTR1BHTR1A | |
| SCHEMBL5209481 | 0.86 | HTR1D (0.57) | HTR1DHTR1BHTR1A | |
| SCHEMBL5211137 | 0.85 | HTR1D (0.68) | HTR1DHTR1BHTR1A | |
| Hydrochloric Acid SCHEMBL5241168 | 0.85 | HTR1D (0.56) | HTR1DHTR1BHTR1A | |
| SCHEMBL5205989 | 0.85 | HTR1D (0.69) | HTR1DHTR1BHTR1A | |
| SCHEMBL5205975 | 0.85 | HTR1D (0.69) | HTR1DHTR1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480972-B1 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1480972-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068760-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | CNR1, HTR5A, HTR1A | HTR1D 6/4885HTR1B 16/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.